The Mark Foundation for Cancer Research – Early Detection Award

Event details
Date | 10.03.2025 |
Category | Call for proposal |
Aim: The projects funded through this initiative will advance our understanding of the origins and risk stratification of recalcitrant cancers and accelerate the development of technological and methodological innovation in early cancer detection and interception. It is recognized that significant barriers to the development and clinical implementation of early detection biomarkers exist, partly due to the need for rigorous testing within randomized clinical trials. Ideas that are broadly applicable to early detection across multiple cancer types are encouraged, including the development of novel clinical trial statistical methodologies that aim to assess the validity of early detection biomarkers.
Proposed research projects must be designed to advance the discovery, technical development, and pre-clinical validation of effective approaches and methods for early cancer detection, or the early clinical evaluation of treatment for pre-malignant disease. Projects focused on cancer prevention rather than early cancer detection and diagnosis are not in the scope of this RFP.
Eligible cancer types:
Duration: 2 years
Eligibility:
Deadline for Letter of Intent: 10 March 2025
Further information
Proposed research projects must be designed to advance the discovery, technical development, and pre-clinical validation of effective approaches and methods for early cancer detection, or the early clinical evaluation of treatment for pre-malignant disease. Projects focused on cancer prevention rather than early cancer detection and diagnosis are not in the scope of this RFP.
Eligible cancer types:
- Pancreatic cancer
- Hepatobiliary cancers (hepatocellular carcinoma, gallbladder and bile duct cancers, cholangiocarcinoma)
- Ovarian cancer
- Glioblastoma
- Upper GI cancers (esophageal, gastric cancer)
- Cancers resulting from hereditary cancer predisposition syndromes
Duration: 2 years
Eligibility:
- Applicants must have an independent faculty research appointment at a non-profit academic, research, or medical institution. There are no restrictions on citizenship or geography for investigators.
- Investigators may apply as a team of two to four investigators (one Principal Investigator and up to three co-investigators). Teams may comprise investigators from a single institution or multiple institutions. There is no requirement to include a US-based institution as part of the team.
- Proposed projects must not be supported by overlapping funding sources. Grantees must disclose any potential overlap with other current or pending research funding.
Deadline for Letter of Intent: 10 March 2025
Further information
- More information about the program is available here
- The application portal can be found here
- For any other questions, please contact the Research Office
Practical information
- General public
- Free
Contact
- research@eplf.ch